In IN RE VALSARTAN, LOSARTAN, AND IRBESARTAN PRODUCTS LIABILITY LITIGATION, Civil No. 19-2875 (D.N.J. 2020) before the Court was Defendant Teva’s request for an Order to forego additional review of documents that based on its own unilaterally developed and administered TAR, were predicted to be non-responsive. Teva alternatively sought to shift to Plaintiffs the cost